|
Per direction by fda in a letter dated, july 20, 2018, this emdr is being filed to submit new information obtained based on the complaint investigation results.The initial report for this event was submitted in the quarter 1 2018 asr report.However, supplemental reports regarding the asr are no longer being accepted.It was agreed upon with the fda that the date of awareness would be the date of the letter received, which is july 20, 2018.Received 5 magic3 intermittent catheter lot samples and 1 comparable sample for evaluation.The reported event was unconfirmed as the products meet specifications.The exterior of the sample was visually inspected and did not find any evidence of a failure that would support the reported event.Per the dimensional evaluation, it was found all samples were within specification for 16 french size.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
|